US8808740 — Encased tamper resistant controlled release dosage forms
Method of Use · Assigned to Purdue Pharma LP · Expires 2031-12-21 · 6y remaining
What this patent protects
This patent protects a controlled-release dosage form of an opioid analgesic, specifically hydrocodone bitartrate, that releases the medication in a proportional amount over 8 to 24 hours.
USPTO Abstract
In certain embodiments, the present invention is directed to a solid controlled release dosage form comprising: a core comprising a first portion of an opioid analgesic dispersed in a first matrix material; and a shell encasing the core and comprising a second portion of the opioid analgesic dispersed in a second matrix material; wherein the amount of opioid analgesic released from the dosage form is proportional within 20% to elapsed time from 8 to 24 hours, as measured by an in-vitro dissolution in a USP Apparatus 1 (basket) at 100 rpm in 900 ml simulated gastric fluid without enzymes (SGF) at 37 C.
Drugs covered by this patent
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-1556 |
— | hydrocodone-bitartrate |
U-1556 |
— | hydrocodone-bitartrate |
U-1556 |
— | hydrocodone-bitartrate |
U-1556 |
— | hydrocodone-bitartrate |
U-1556 |
— | hydrocodone-bitartrate |
U-1556 |
— | hydrocodone-bitartrate |
U-1556 |
— | hydrocodone-bitartrate |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.